Validating country documents
As a result of the FDA's Part 11 policy supporting the use of electronic records and digital signatures in lieu of paper, US organizations involved in U. clinical trials can move from a paper-based TMF to an electronic TMF (e TMF), and still be in compliance with FDA regulatory policies.
The definition of what comprises an e TMF is defined by the regulatory agency with jurisdiction over the clinical trial.
It is a type of content management system for the pharmaceutical industry, providing a formalized means of organizing and storing documents, images, and other digital content for pharmaceutical clinical trials that may be required for compliance with government regulatory agencies.
The term e TMF encompasses strategies, methods and tools used throughout the lifecycle of the clinical trial regulated content.
Membership in the OASIS e TMF Standard TC was opened to anyone in September 2013; membership in the OASIS e TMF Standard TC remains open to anyone who wishes to join and the work of the TC is open to public comment and review.
All work of the OASIS e TMF standard TC is available freely under OASIS open source IPR policies.
As a result of the lack of a standard to represent e TMF content, e TMF information interoperability and content exchange between systems and applications is inefficient.
Depending on the regulatory jurisdiction, this information is typically stored in the trial master file or TMF.Validating documents for countries that do not participate in the Hague Convention can be difficult and time-consuming.It may take several steps depending on the target country. citizens, and foreign nationals on all documents that will be used in foreign countries.However, if a clinical trial elects to store trial master file 'essential documents' in electronic format, then the e TMF system used to store those files is subject to regulatory controls specified under FDA Title 21 CFR Part 11.With respect to the FDA, the required components, controls and policies for an e TMF used in US based clinical trials follow US FDA CFR 21 Part 11 requirements.